跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NYPOZI - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
NYPOZI
Authorized
STANDARD
NYPOZI
TANVEX BIOPHARMA USA, INC.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
3b99b972b59af4b8
Company
TANVEX BIOPHARMA USA, INC.
Type
Standard
Approval Details
Approval Id
3b99b972b59af4b8
Drug Approval Canada Name
NYPOZI
Product Name
NYPOZI
Status
Marketed
Status Date
2024-01-24
Original Market Date
2024-01-24
Din
02521008
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous , Subcutaneous
Schedule
Schedule D , Prescription
Ahfs
20:16.00
Atc Original
L03AA02 FILGRASTIM
Atc Name
l 03 aa 02
Aig Number
0123525003
Company Name
TANVEX BIOPHARMA USA, INC.
Company Address
10394 Pacific Center Court, San Diego, California, United States, 92121
Company Detail Path
/organization/tanvex-biopharma-usa-inc
Company Information
Pharmaceutical Company Name
TANVEX BIOPHARMA USA, INC.
Country Name
United States
Province Name
California
City Name
加利福尼亚州圣迭戈县
Address
10421 Pacific Center Ct
Active Ingredients
FILGRASTIM
480 MCG / 0.8 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
3b99b972b59af4b8
Type
Standard
Back to Health Canada Approvals